Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 8/20 | 0.51 |
| ▸ | FPR2 | P25090 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470342 | 1.00 | DPP4 (0.53) | DPP4FPR1FPR2ALDH1A1CYP3A4 | |
| SCHEMBL4470331 | 1.00 | DPP4 (0.53) | DPP4FPR1FPR2ALDH1A1CYP3A4 | |
| SCHEMBL2934742 | 0.88 | DPP4 (0.67) | DPP4FPR1FPR2ALDH1A1KMT2A | |
| SCHEMBL2934740 | 0.88 | DPP4 (0.67) | DPP4FPR1FPR2ALDH1A1KMT2A | |
| SCHEMBL2934745 | 0.88 | DPP4 (0.67) | DPP4FPR1FPR2ALDH1A1KMT2A | |
| SCHEMBL19972292 | 0.87 | FPR1 (0.58) | FPR1FPR2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL757492 | 0.85 | DPP4 (0.55) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL757493 | 0.85 | DPP4 (0.55) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL757491 | 0.85 | DPP4 (0.55) | DPP4ALDH1A1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL755965 | 0.84 | DPP4 (0.52) | DPP4FPR1FPR2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258894-A1 | Fused Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885FPR1 3332/4885FPR2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.